Cytoplasmic expression of β-catenin is an independent predictor of progression of conventional renal cell carcinoma

• Verfasst von: Kovacs, Gyula [VerfasserIn]
• Verfasst von: Kaerger, Nina [VerfasserIn]
• Titel: Cytoplasmic expression of β-catenin is an independent predictor of progression of conventional renal cell carcinoma
• Titelzusatz: a simple immunostaining score
• Verf.angabe: Gyula Kovacs, Nina Kaerger Billfeldt, Nelli Farkas, Timea Dergez, Andras Javorhazy, Daniel Banyai, Csaba Pusztai & Arpad Szanto
• Jahr: 2017
• Umfang: 8 S.
• Fussnoten: Gesehen am 31.10.2018 ; First published: 08 August 2016
• Titel Quelle: Enthalten in: Histopathology
• Ort Quelle: Oxford [u.a.] : Wiley-Blackwell, 1977
• Jahr Quelle: 2017
• Band/Heft Quelle: 70(2017), 2, Seite 273-280
• ISSN Quelle: 1365-2559
• DOI: doi:10.1111/his.13059
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: biomarker
• Sach-SW: immunochemistry
• Sach-SW: postoperative progression
• Sach-SW: renal cancer
• Sach-SW: β-catenin
• K10plus-PPN: 1582448418

Abstract

Aims The aims of this study were to investigate the potential of β-catenin as a biomarker for predicting cancer-specific survival, and to find a reproducible mode of evaluation of immunohistochemistry. Methods and results β-Catenin expression was analysed by immunohistochemistry in a cohort of 488 patients with conventional renal cell carcinoma (RCC) operated on between 2000 and 2010. The association between β-catenin expression and cancer-specific survival was assessed with univariate and multivariate Cox regression models in relation to conventional clinical pathological prognostic factors, and by Kaplan-Meier survival analysis with the log rank test. The univariate Cox regression model revealed an association of cytoplasmic β-catenin positivity and pathological variables with cancer-specific death. The multivariate Cox regression model analysis of tumours without metastatic disease at the first presentation identified the T-classification (P < 0.001) and cytoplasmic β-catenin positivity as risk factors for postoperative tumour progression. Specifically, cytoplasmic β-catenin expression was an independent factor indicating an unfavourable prognosis, with a four-fold higher risk of cancer-specific death (relative risk 4.017; 95% confidence interval 2.489-6.482; P < 0.001). The median survival time for patients with tumours showing cytoplasmic accumulation of β-catenin was 48 months, whereas the overall survival time was 166 months. Conclusions Cytoplasmic β-catenin expression is an independent prognostic factor for conventional RCC, and may help to identify patients with a high risk of cancer-specific death and to direct optimized active surveillance or adjuvant therapy.